Cannabigerol (CBG for short) is the first Cannabinoid that forms in the cannabis plant. CBG is the substance that makes it possible for CBD and the psychoactive substance THC to form in the first place. However, most types of hemp only contain very small amounts of CBG (<1%).
CBG is a Phytocannabinoid. These molecules cannot not be created by the human body – as opposed to Endocannabinoids. Cannabigerol is a non-psychoactive Cannabinoid, just like CBD, so it doesn’t make users “high”. In contrast to CBD, CBG hasn’t gotten very much attention, since its low concentration hasn’t attracted much research.
Scientists at the University of Reading have discovered in a study with two rats that the effect of CBG increases the appetite. Further, studies suggest that CBG can reduce the growth of certain tumours. Just like with CBD, the Department of Pharmacy at the University of Naples has conducted research on the effect of CBG on intestinal diseases.
The study found that CBG can have an infection-reducing effect, just like CBD. The CBG effect on the GABA-neurotransmission in the brain can also reduce pain. However, as opposed to the research on CBD, studies on CBG are still in their infancy.
Read more about CBG in our blog post.